HOME | COUNTRIES | CITIES | COMPANIES | SPORTS | CARS
news videos images websites wiki
 

Gilead Sciences NEWS

NFE/5.0en-USnews-webmaster@google.com2019 Google Inc.Thu, 14 Feb 2019 08:25:09 GMTGoogle News
Why Gilead Sciences Stock Perked Up in January  The Motley Fool

Shares of Gilead Sciences (NASDAQ:GILD) gained 11.9% over the course of January, according to data from S&P Global Market Intelligence. Why were ...

The Motley Fool
Is Gilead Sciences a Bad News Buy?  Motley Fool

Gilead's fourth-quarter numbers failed to hit the mark, but the company firmly believes that better days are directly ahead.

Motley Fool
Gilead: What A Difference An O'Day Can Make  Seeking Alpha

GILD reported some ugly one-time charges in Q4, but with new management, no one cares. Uncertainties abound - more than usual for this industry - but it's ...

Seeking Alpha
Why Gilead Sciences Stock Sank by 12.7% in 2018  Motley Fool

Gilead's stock churned lower yet again last year, but the biotech could finally be nearing an inflection point.

Motley Fool
Gilead Sciences Stock Could Have Plenty of Upside, Analyst Says  Barron's

Gilead Sciences stock could get a big boost from drug trial data expected this quarter, Citigroup says.

Barron's
Gilead Sciences Q4 Earnings Preview  Seeking Alpha

Gilead Sciences (NASDAQ:GILD) is scheduled to announce Q4 earnings results on Monday, February 4th, after market close. The consensus EPS Estimate is ...

Seeking Alpha
Killer Stocks to Buy That No One Knows About: Gilead Sciences, Inc. (GILD), Delta Air Lines, Inc. (DAL)  Financial Mercury

The shares of Gilead Sciences, Inc. (NASDAQ:GILD) has been pegged with a rating of Market Perform by Wells Fargo in its latest research note that was ...

Financial Mercury
Victory over Gilead! California Court Rules HIV Drug Personal Injury Cases May Proceed  Associated Press

LOS ANGELES--(BUSINESS WIRE)--Feb 13, 2019--HIV/AIDS patients and advocates are celebrating a California court ruling that allows personal injury cases ...

Associated Press
Call Buying Activity in Gilead Sciences (GILD) Highlights 'Speculative Bullish Sentiment' in Shares -Susquehanna  StreetInsider.com

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

StreetInsider.com
Critical Research: Gilead Sciences (GILD) & Titan Pharmaceuticals (TTNP)  BharataPress

Gilead Sciences (NASDAQ:GILD) and Titan Pharmaceuticals (NASDAQ:TTNP) are both medical companies, but which is the superior business? We will ...

BharataPress
PhRMA Welcomes Genentech and Gilead Sciences to Association  PRNewswire

WASHINGTON, Jan. 17, 2019 /PRNewswire/ -- The Pharmaceutical Research and Manufacturers of America (PhRMA) announced today that Genentech, ...

PRNewswire
Here is How To Play Bottom in Gilead Sciences, Inc. (GILD), Kinross Gold Corporation (KGC)  Post Analyst

Gilead Sciences, Inc. (NASDAQ:GILD) recent drop took place on significantly more volume which surged nearly 15548977 contracts on 12-Feb-19 versus its ...

Post Analyst
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know  Zacks.com

Gilead Sciences (GILD) closed the most recent trading day at $69.83, moving +0.34% from the previous trading session.

Zacks.com
Better Buy: Biogen vs. Gilead Sciences  The Motley Fool

Juggernauts. That's not a word most of us use very often. But it's a pretty good description of Biogen (NASDAQ:BIIB) in multiple sclerosis (MS). It's also applicable ...

The Motley Fool
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know  Zacks.com

Gilead Sciences (GILD) closed at $68.52 in the latest trading session, marking a +1.89% move from the prior day.

Zacks.com
Gilead Sciences, Inc. (GILD) stands -2.88% away from 50 SMA: Technical Watch  Stocks Gallery

Gilead Sciences, Inc. (GILD) Stock Price Trading Overview: Gilead Sciences, Inc. (GILD) dropped with negative flow of -3.37% during recent week and go up so ...

Stocks Gallery
Gilead Misses Mark on Earnings as Daniel O'Day Prepares to Take Helm  Bloomberg

Gilead Sciences Inc. posted fourth-quarter earnings that missed expectations as the biotechnology giant fends off threats to its best-selling drugs and prepares ...

Bloomberg
Private Capital Advisors Increased Gilead Sciences (GILD) Position by $340,000; Stock Declined; St Germain DJ Co Has Lowered Stake in Palo Alto Networks Com (PANW) by $2.38 Million as Share Value Declined  The Hi New Ulm

Private Capital Advisors Inc increased its stake in Gilead Sciences Inc (GILD) by 51.79% based on its latest 2018Q3 regulatory filing with the SEC. Private St ...

The Hi New Ulm
Gilead Sciences Inc. (GILD) and Iterum Therapeutics plc (NASDAQ:ITRM) Comparison side by side  The Yomi Blog

Gilead Sciences Inc. (NASDAQ:GILD) and Iterum Therapeutics plc (NASDAQ:ITRM) compete with each other in the Biotechnology sector. We will analyze and ...

The Yomi Blog
Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for  Zacks.com

Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key ...

Zacks.com
Here's Why Viking Therapeutics Rose as Much as 13.9% Today  Motley Fool

Shares of Viking Therapeutics (NASDAQ:VKTX) jumped nearly 14% today after Gilead Sciences (NASDAQ:GILD) announced that a closely watched drug ...

Motley Fool
Liver Cirrhosis Therapeutics Drugs-Global Market Outlook 2019 to 2025 | Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, Roche  Nevada Green Times

The report provides a unique tool for evaluating the Market, highlighting opportunities, and supporting strategic and tactical decision-making. This report ...

Nevada Green Times
Nymox Pharmaceutical Corporation (NYMX) and Gilead Sciences Inc. (NASDAQ:GILD) Comparison side by side  Thе Mоnіtоr

Both Nymox Pharmaceutical Corporation (NASDAQ:NYMX) and Gilead Sciences Inc. (NASDAQ:GILD) are Biotechnology companies, competing one another.

Thе Mоnіtоr
Gilead Sciences to Release Fourth Quarter and Full Year 2018 Financial Results on Monday, February 4, 2019  Business Wire

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2018 financial results will be released on Monday, February.

Business Wire
Placing Gilead Sciences, Inc. (NasdaqGS:GILD)'s Valuation Under Review  Bedford Journal

Gilead Sciences, Inc. (NasdaqGS:GILD) has an ERP5 rank of 3122. The ERP5 Rank is an investment tool that analysts use to discover undervalued.

Bedford Journal
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know  Zacks.com

Gilead Sciences (GILD) closed at $68.25 in the latest trading session, marking a -0.44% move from the prior day.

Zacks.com
Comparing Valuation With Peers: Gilead Sciences, Inc. (GILD), EyePoint Pharmaceuticals, Inc. (EYPT)  Post Analyst

Gilead Sciences, Inc. (NASDAQ:GILD) is expensive when one looks at the company's price to sales ratio of 3.94 and compares it with other companies in the ...

Post Analyst
1 Chart That Shows Why Celgene Has Been Bought Out and Gilead Hasn't (Yet)  The Motley Fool

At the start of the year, Gilead Sciences (NASDAQ:GILD) and Celgene (NASDAQ:CELG) were arguably the biggest value plays in the biotech industry. Gilead ...

The Motley Fool
2 Stocks to Watch Today: Sibanye Gold Limited (SBGL), Gilead Sciences, Inc. (GILD)  MONReport

Sibanye Gold Limited (NYSE: SBGL) experienced a high price of $4.21 with a low value of $4.065 at the end of the last trading session, which followed after a ...

MONReport
Keryx Biopharmaceuticals Inc. (KERX)'s Financial Results Comparing With Gilead Sciences Inc. (NASDAQ:GILD)  Thе Mоnіtоr

We will be comparing the differences between Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) and Gilead Sciences Inc. (NASDAQ:GILD) as far as dividends, ...

Thе Mоnіtоr
Gilead Sciences Inc. (GILD) and Akcea Therapeutics Inc. (NASDAQ:AKCA) Comparison side by side  Port Courier

Gilead Sciences Inc. (NASDAQ:GILD) and Akcea Therapeutics Inc. (NASDAQ:AKCA) are two firms in the Biotechnology that compete against each other.

Port Courier
Reviewing Cerus Corporation (CERS)'s and Gilead Sciences Inc. (NASDAQ:GILD)'s results  EN Digest

Cerus Corporation (NASDAQ:CERS) and Gilead Sciences Inc. (NASDAQ:GILD), both competing one another are Biotechnology companies. We will compare ...

EN Digest
Tracking the Indicators on Shares of Gilead Sciences Inc (GILD)  Weston Business Review

Tracking medium-term indicators on shares of Gilead Sciences Inc (GILD), we have noted that the reading from the 40-day commodity channel index is currently ...

Weston Business Review
Analyst: Intercept (NASDAQ:ICPT)'s NASH Drug Could Launch Sans Competition After Gilead (NASDAQ:GILD) Trial Failure  Benzinga

With Gilead Sciences, Inc. (NASDAQ: GILD)'s NASH setback, Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT)'s Ocaliva, which is being evaluated in a ...

Benzinga
Gilead Sciences Inc (GILD): Share Price Drips Lower -4.05%  Martin Business Telegraph

After a recent check, we have noted that Gilead Sciences Inc (GILD) shares have dropped -4.05% lower over the past 4-weeks. Checking on performance over ...

Martin Business Telegraph
Calculating The Fair Value Of Gilead Sciences, Inc. (NASDAQ:GILD)  Simply Wall St

I am going to run you through how I calculated the intrinsic value of Gilead Sciences, Inc. (NASDAQ:GILD) by estimating the company's future cash flows and ...

Simply Wall St
As Gilead Sciences (GILD) Valuation Declined, Steinberg Global Asset Management Has Raised Holding; Reynders Mcveigh Capital Management Trimmed Its Procter & Gamble Co (PG) Stake as Valuation Rose  The Yomi Blog

Steinberg Global Asset Management increased its stake in Gilead Sciences Inc (GILD) by 13.55% based on its latest 2018Q3 regulatory filing with the SEC.

The Yomi Blog
2 Will Gilead Sciences' Q4 2018 Revenues Impress Markets?  Market Realist

In the third quarter of 2018, Gilead Sciences (GILD) reported revenues of $5.60 billion, which is a YoY decline of 14.07%.

Market Realist
Gilead Sciences (GILD) Stock closed with change of -3.28% to $65.4  News Leading

Volatility Insights. Watching some historical volatility numbers on shares of Gilead Sciences (GILD) we can see that the 30 days volatility is presently 2.07%.

News Leading
Edgar Lomax Co Has Trimmed Position in Gilead Sciences Com (GILD) by $346,500 as Stock Value Declined; Stieven Capital Advisors LP Has Cut Qcr Holdings (QCRH) Stake by $4.64 Million; Stock Price Declined  The Yomi Blog

Edgar Lomax Co decreased its stake in Gilead Sciences Inc Com (GILD) by 3.31% based on its latest 2018Q3 regulatory filing with the SEC. Edgar Lomax Co ...

The Yomi Blog
Gilead Sciences, Inc. (NASDAQ:GILD) Will Allow Generic Drugs Manufacturers To Make New Version Of Sovaldi  Stocks Beat

Gilead Sciences, Inc. (NASDAQ:GILD) was planning to launch its blockbuster hepatitis C drug Sovaldi in India by June, the company announced before US ...

Stocks Beat
A Value Opportunity In Occidental Petroleum Corporation (OXY), Gilead Sciences, Inc. (GILD)  GV Times

18 analysts out of 26 Wall Street brokerage firms rate Occidental Petroleum Corporation (NYSE:OXY) as a Buy, while 0 see it as a Sell. The rest 8 describe it as a ...

GV Times
Investors Secrets on Gilead Sciences, Inc. (GILD), ServiceMaster Global Holdings, Inc. (SERV)  MONReport

Gilead Sciences, Inc. (NASDAQ: GILD) experienced a high price of $69 with a low value of $67.36 at the end of the last trading session, which followed after a ...

MONReport
Recent Fundamentals: – Gilead Sciences, Inc., (NASDAQ: GILD)  Nyse NewsToday

The Relative Strength Index (RSI) is a technical indicator used in the analysis of financial markets. It is intended to chart the current and historical strength or ...

Nyse NewsToday
Executives On The Move: Departures and Arrivals at Endologix, Gilead Sciences and Perrigo  Scrip

Endologix CEO makes a switch to CEO at Vascular Therapies, and Clinical Research and Commercial VPs exit Gilead Sciences. Plus, producer of OTC and ...

Scrip
Latest Brokerage Rating: Rite Aid Corporation (RAD), Gilead Sciences, Inc. (GILD)  MONReport

Rite Aid Corporation (NYSE: RAD) experienced a high price of $0.96 with a low value of $0.93 at the end of the last trading session, which followed after a loss ...

MONReport
Short Sellers Back Off Major Biotechs  24/7 Wall St.

The January 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.

24/7 Wall St.
A Sober View On The Procter & Gamble Company (PG), Gilead Sciences, Inc. (GILD)  GV Times

The Procter & Gamble Company (NYSE:PG) 14-day RSI (relative strength index) score is 55.28, which shows that its stock has been neutral. The 20-day ...

GV Times
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Northside Capital Management LLC  Fairfield Current

Northside Capital Management LLC increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.2% in the fourth quarter, according to the ...

Fairfield Current
Gilead Sciences (GILD) estimated to arrive at $84.58 in 1 Year period  Voice Of Analysts

Gilead Sciences (GILD) stock managed performance -3.90% over the last week and switched with performance of -1.19% throughout past one month period.

Voice Of Analysts
These stock’s have rarely let down their Holders: Gilead Sciences, Inc. (GILD), Citizens Financial Group, Inc. (CFG)  MONReport

Gilead Sciences, Inc. (NASDAQ: GILD) experienced a high price of $70.3 with a low value of $68.6 at the end of the last trading session, which followed after a ...

MONReport
Many Investors Taking a Second Look at Gilead Sciences, Inc. (NASDAQ:GILD) After Recent Market Moves  The Coin Guild

Gilead Sciences, Inc. (NASDAQ:GILD) has been in the news after the price of the stock hit $67.47 at the conclusion of the most recent close. The stock is traded ...

The Coin Guild
2 Stocks to Watch Today: Walgreens Boots Alliance, Inc. (WBA), Gilead Sciences, Inc. (GILD)  MONReport

Walgreens Boots Alliance, Inc. (NASDAQ: WBA) experienced a high price of $72.88 with a low value of $71.96 at the end of the last trading session, which ...

MONReport
Agency Mania Solutions Presents with Gilead Sciences and HP Inc. at ANA Advertising Financial Management Committee West Coast Chapter Meeting  PR Web

Seattle (PRWEB) January 23, 2019 -- Agency Mania Solutions' Co-Founder, Bruno Gralpois, and Gilead Sciences' Senior Director of Marketing Operations, ...

PR Web
It’s Again Time To Consider The Kraft Heinz Company (KHC), Gilead Sciences, Inc. (GILD)  The RNS Daily

KHC trading volume has added 1187564 shares compared to readings over the past three months as it recently exchanged 8277564 shares. This means there ...

The RNS Daily
Critical Factors Ahead For Gilead Sciences, Inc. (GILD), The Kraft Heinz Company (KHC)  GV Times

The price of Gilead Sciences, Inc. (NASDAQ:GILD) went down by -$0.63 now trading at $68.55. Their shares witnessed a 13.64% increase from the 52-week low ...

GV Times
Arvest Bank Trust Division Decreases Position in Gilead Sciences, Inc. (NASDAQ:GILD)  Baseball Daily News

Arvest Bank Trust Division reduced its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.1% in the 4th quarter, according to the company in its ...

Baseball Daily News
Analysts (Still) In Love With Boston Scientific Corporation (BSX), Gilead Sciences, Inc. (GILD)  GV Times

20 analysts out of 22 Wall Street brokerage firms rate Boston Scientific Corporation (NYSE:BSX) as a Buy, while 0 see it as a Sell. The rest 2 describe it as a ...

GV Times
Gilead Sciences, Inc. (GILD) Expected to Announce Quarterly Sales of $5.52 Billion  Modern Readers

Analysts expect Gilead Sciences, Inc. (NASDAQ:GILD) to post $5.52 billion in sales for the current fiscal quarter, according to Zacks. Eight analysts have made ...

Modern Readers
Where Will Gilead Sciences, Inc. Be in 5 Years?  The Motley Fool

Gilead Sciences (NASDAQ:GILD) is in a slump. Over the past three years, the biotech's stock has lost over 35% of its value, thanks to falling hepatitis C sales, ...

The Motley Fool
3 Biotechs Gilead Sciences Could Buy in March  The Motley Fool

With a new CEO from Roche on the way, these companies' odds of being acquired just rose a notch.

The Motley Fool
7 Things to Expect for Gilead Sciences in 2019  The Motley Fool

The big biotech's executives spill the beans on plans for the new year at the J.P. Morgan Healthcare Conference.

The Motley Fool
Gilead Sciences: Top Biotech Pick For The Next Decade With An Options Play  Seeking Alpha

Gilead Sciences has focused on stabilizing its Hepatitis C revenues while steadily increasing its HIV revenues. The company has been improving margins.

Seeking Alpha
Is 2019 The Turnaround Year For Gilead Sciences?  Seeking Alpha

Following precipitous revenue losses attributable to its portfolio of HCV medicines, Gilead finds itself in improving financial straits. 2019 will see the relea.

Seeking Alpha
Could Gilead Sciences Be the Next Big Biotech Target?  Barron's

An analyst upgrade—and renewed interest in biotechs after Bristol-Myers Squibb announced a deal to buy Celgene—have help Gilead's stock rise.

Barron's
Here's Why Gilead Sciences Lost $12.1 Billion in December  Motley Fool

Shares of former biotech darling Gilead Sciences (NASDAQ:GILD) fell 13.1% in December, according to data from S&P Global Market Intelligence. The last ...

Motley Fool
Why Gilead Sciences, Inc. Stock Broke Down in October  Motley Fool

Shares of biotech giant Gilead Sciences (NASDAQ:GILD) lost a staggering 12.5% of their value in October, according to data from S&P Global Market ...

Motley Fool
Gilead Sciences: Still My Top Biotech Pick For The Next Decade  Seeking Alpha

Gilead Sciences' stock hasn't done much of anything over the past year. However, the story remains the same. Gilead Sciences has a number of exciting ...

Seeking Alpha
What's Next for Gilead Sciences After Its Latest Clinical Success  Motley Fool

Gilead executives talk about the future after reporting positive late-stage results for the company's experimental rheumatoid arthritis drug.

Motley Fool
Forget Gilead Sciences' CEO Departure -- This Was the Biotech's Big News  Motley Fool

These four major stories are more important to the biotech's future than its CEO leaving unexpectedly.

Motley Fool
Better Buy: Gilead Sciences vs. Celgene  The Motley Fool

These big biotechs are due for a comeback. But which is likely to enjoy the biggest bounce?

The Motley Fool
Gilead Sciences (GILD) Appoints Daniel O'Day as New CEO  Zacks.com

Gilead Sciences (GILD) names Roche's Daniel O'Day as the company's new Chairman and CEO.

Zacks.com
Better Buy: Gilead Sciences, Inc. vs. Pfizer  The Motley Fool

Both have made some strange moves lately, but which is the better stock to buy now?

The Motley Fool
Gilead Sciences Gets A Much-Needed Confirmation Boost For Yescarta  Seeking Alpha

Gilead announced positive 2-year results treating patients with refractory large B-cell lymphoma after only a single infusion of Yescarta. At 2 years, 83% of pa.

Seeking Alpha
Gilead Sciences (GILD) Q3 2018 Results - Earnings Call Transcript  Seeking Alpha

Gilead Sciences, Inc. (NASDAQ:GILD)Q3 2018 Earnings CallOctober 25, 2018 4:30 pm ETExecutivesSung Lee - Gilead Sciences, Inc.Robin L. Washington ...

Seeking Alpha
Gilead: The New CEO Will Need More Time  Seeking Alpha

Gilead recently announced the appointment of the new CEO, the current CEO of Roche Pharmaceuticals. There are multiple delays associated with the ...

Seeking Alpha
Agenus Gets Hail Mary Cash Infusion From Gilead Sciences  Seeking Alpha

Agenus established an immuno-oncology pact with Gilead Sciences in a deal totaling about $1.8 billion. The partnership is established to advance up to 5 novel ...

Seeking Alpha
Better Buy: Celgene Corporation vs. Gilead Sciences  Motley Fool

Which big biotech is the better stock pick at the moment?

Motley Fool
Be ready to Ride the Dividend on Gilead Sciences  TheStreet.com

If you are buying into Gilead Sciences' (GILD) better-than-expected earnings, be ready to ride the dividend, because you won't see price growth this year.

TheStreet.com
Is Gilead Sciences' Sudden Change in Leadership a Good Thing?  The Motley Fool

Gilead Sciences (NASDAQ:GILD) announced last week that CEO John Milligan and Chairman John Martin will step down from their respective positions later ...

The Motley Fool
Gilead Sciences and Scholar Rock Announce Strategic Collaboration to Develop Novel Therapies for Fibrotic Diseases  Business Wire

Gilead Sciences, Inc. (NASDAQ: GILD) and Scholar Rock Holding Corporation (NASDAQ: SRRK) announced today that the companies have entered into a ...

Business Wire
CEO Departure at Gilead Sciences Upstages Good Second-Quarter Results  Motley Fool

The big biotech announced great momentum for its new HIV drug, a hint at HCV sales stabilization, and news that its CEO is stepping down.

Motley Fool
Gilead Sciences' Latest Tactic? Go Generic  The Motley Fool

The company plans to launch generic versions of its top hepatitis C drugs to insulate itself against competition.

The Motley Fool
Gilead: The Good, The 'Meh' And The Ugly  Seeking Alpha

GILD reported Q3 late last week, and the stock held up well in a down tape. While GILD may be insulated from the administration's latest cost-cutting plans, tha.

Seeking Alpha
Gilead Remains A Sell  Seeking Alpha

GILD's Q3 revenue declined Q/Q. HCV was a non-factor, but Q1 2019 generic offerings could change things. I expect attractive M&A opportunities to materialize ...

Seeking Alpha
Is Now a Good Time to Buy Gilead Sciences?  Motley Fool

Trial results for promising drugs may help the company turn the corner, but declining sales remain a problem.

Motley Fool
Gilead Doubles Down On Its NASH Pipeline With $1.5B Deal  Seeking Alpha

Gilead Sciences establishes strategic collaboration with Scholar Rock Holding Corporation in a deal totaling $1.5 billion. To get the program started, Gilead on.

Seeking Alpha
Will Investors Find A Nektar Balm In Gilead?  Seeking Alpha

Nektar Therapeutics has announced a collaboration with Gilead Sciences. The companies will work together on a virology drug program. Both Nektar and ...

Seeking Alpha
Gilead Sciences: We're Not In Bull Territory Yet  Seeking Alpha

I view the biopharm company as a hold. With a continually slowing product line, the new initiatives are not yet offsetting slowing products. Until the firm can.

Seeking Alpha
Gilead Sciences Commits $150M to Agenus in Cancer Drug R&D Pact  Xconomy

For the second time this week, Gilead Sciences has partnered with a Boston-area biotech, this time with a deal that covers up to five experimental cancer.

Xconomy
Gilead Sciences, Inc. (GILD) Management Presents at The Evercore ISI HealthCONx Conference 2018 (Transcript)  Seeking Alpha

Gilead Sciences, Inc. (NASDAQ:GILD) Evercore ISI HealthCONx Conference November 27, 2018, 09:30 AM ET Executives Robin Washington - EVP & CFO ...

Seeking Alpha
Gilead paid $510M for drug and just sold it for $3 million  CNBC

A drug at the center of a $510 million deal five years ago by Gilead Sciences was sold by the Foster City-based drug developer for $3 million. The buyer, Sierra ...

CNBC
Gilead Is Gearing Release Of NASH Results Soon, But Other Deals Are Still Rolling In  Seeking Alpha

Gilead Sciences continues to make a strong push for partnering with or acquiring NASH companies to solidify a stronghold in this space. Results from two ...

Seeking Alpha
Gilead Is On Hold For Now  Seeking Alpha

Gilead is too focused on HIV, where it mainly plays an adherence game. CEO is leaving by the end of the year, given the board's assumed desire to expand ...

Seeking Alpha
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know  Zacks.com

In the latest trading session, Gilead Sciences (GILD) closed at $61.88, marking a -1.68% move from the previous day.

Zacks.com
Better Buy: Gilead Sciences, Inc. vs. Amgen Inc.  Motley Fool

Which of these dividend-paying biotech stocks is the better pick right now?

Motley Fool
What's Next For Gilead?  Seeking Alpha

Gilead's sales trends are improving. HIV sales continue to rise, Yescarta is ramping up, and HCV sales are seemingly stabilizing. There are near-term positives,

Seeking Alpha
Biotech Stocks Gilead and Biogen Have Room to Bounce Back  Barron's

Gilead Sciences and Biogen stock have some upside, after sliding n 2018, analysts say. Questions about sales of Biogen's Spinraza treatment still weigh on its ...

Barron's
Forget Gilead Sciences: Intercept Pharmaceuticals, Inc. Is a Better Growth Stock  Motley Fool

Gilead's high-flying days are seemingly over. Intercept Pharmaceuticals, on the other hand, is only getting started.

Motley Fool
 

Gilead Sciences Videos

Gilead Sciences, Inc: A Commitment To Innovation
10:50:19
Gilead Sciences, Inc: A Commitment To Innovation
Gilead Sciences
17:59:12
Gilead Sciences
Gilead Sciences reports quarterly earnings miss
22:00:33
Gilead Sciences reports quarterly earnings miss
What's Gilead Sciences Doing With All That Cash?
17:39:09
What's Gilead Sciences Doing With All That Cash?
GILEAD ENVIRONMENT (FOSTER CITY)
06:16:42
GILEAD ENVIRONMENT (FOSTER CITY)
Technician reacts to Gilead earnings and the biotech space
21:56:51
Technician reacts to Gilead earnings and the biotech space
How can a single pill treat HIV? (Sponsored by Gilead)
14:00:02
How can a single pill treat HIV? (Sponsored by Gilead)
Gilead to Buy Kite for $11.9 Billion in Cancer Megadeal
17:27:59
Gilead to Buy Kite for $11.9 Billion in Cancer Megadeal
Dr. Michael Riordan Gilead Sciences founder, CEO Chairman interview 1994
14:21:11
Dr. Michael Riordan Gilead Sciences founder, CEO Chairman interview 1994
Gilead Sciences
22:23:52
Gilead Sciences
 

Gilead Sciences Images

Why Gilead (NASDAQ: GILD) chose SoCal for its new ...
Why Gilead (NASDAQ: GILD) chose SoCal for its new ...
Gilead Sciences Tenant Improvement | FPB Architects
Gilead Sciences Tenant Improvement | FPB Architects
These Analysts Neutral On Gilead Sciences, Inc. (GILD ...
These Analysts Neutral On Gilead Sciences, Inc. (GILD ...
Gilead expands UK presence with new London HQ | Pharmafile
Gilead expands UK presence with new London HQ | Pharmafile
Fireside Chat With John F. Milligan, PhD, President and ...
Fireside Chat With John F. Milligan, PhD, President and ...
Stockley Park - Wikipedia
Stockley Park - Wikipedia
FDA Clears Tenofovir Alafenamide (Vemlidy) for Chronic HBV
FDA Clears Tenofovir Alafenamide (Vemlidy) for Chronic HBV
Leading Web Application Development Company | Plego ...
Leading Web Application Development Company | Plego ...
Vemlidy (tenofovir alafenamide) - Hep
Vemlidy (tenofovir alafenamide) - Hep
Viread - FDA prescribing information, side effects and uses
Viread - FDA prescribing information, side effects and uses
 

Gilead Sciences WebSites

 

Gilead Sciences Wiki

Gilead Sciences, Inc., commonly known as Gilead Sciences or Gilead (also styled GILEAD) , is an American biotechnology company that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.Headquartered and founded in Foster City, California, Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500.